The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

The Impact of Pcsk-9 Inhibition on PET CFR in Patients at High CV Risk — Stella

Home/Stable Coronary Disease/

View on ClinicalTrials.gov

Recruiting

Back to Stable Coronary Disease trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Brigham and Women's Hospital, Boston, Massachusetts

Key details

Phase

Post-approval study

Sponsor

Brigham and Women's Hospital

Enrollment target

~50 participants

Started

March 2022

Primary completion

March 2027

Age range

50 Years – 90 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.